48,466
edits
Difference between revisions of "Cholangiocarcinoma"
Jump to navigation
Jump to search
→IHC
Jensflorian (talk | contribs) |
(→IHC) |
||
| Line 95: | Line 95: | ||
*[[AFP]] -ve.<ref name=stc6dec2010>STC. 6 December 2010.</ref> | *[[AFP]] -ve.<ref name=stc6dec2010>STC. 6 December 2010.</ref> | ||
Others: | |||
*CA125 +ve/-ve (30 +ve of 63 cases<ref name=pmid22286058>{{Cite journal | last1 = Higashi | first1 = M. | last2 = Yamada | first2 = N. | last3 = Yokoyama | first3 = S. | last4 = Kitamoto | first4 = S. | last5 = Tabata | first5 = K. | last6 = Koriyama | first6 = C. | last7 = Batra | first7 = SK. | last8 = Yonezawa | first8 = S. | title = Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. | journal = Pathobiology | volume = 79 | issue = 2 | pages = 101-6 | month = | year = 2012 | doi = 10.1159/000335164 | PMID = 22286058 }}</ref>). | |||
Note: | |||
*''MUC-1'' is also known as ''[[EMA]]''. | |||
===Hepatocellular carcinoma versus cholangiocarcinoma=== | |||
ICC vs. HCC:<ref name=pmid19173916>[Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma] Dong H, Cong WL, Zhu ZZ, Wang B, Xian ZH, Yu H. Zhonghua Zhong Liu Za Zhi. 2008 Sep;30(9):702-5. Chinese. PMID 19173916.</ref> | ICC vs. HCC:<ref name=pmid19173916>[Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma] Dong H, Cong WL, Zhu ZZ, Wang B, Xian ZH, Yu H. Zhonghua Zhong Liu Za Zhi. 2008 Sep;30(9):702-5. Chinese. PMID 19173916.</ref> | ||
*ICC: [[CK19]] (92.5%), [[MUC-1]] (73.8%) +ve. | *ICC: [[CK19]] (92.5%), [[MUC-1]] (73.8%) +ve. | ||
| Line 101: | Line 108: | ||
HCC vs. ICC:<ref name=pmid16627262>{{cite journal |author=Lei JY, Bourne PA, diSant'Agnese PA, Huang J |title=Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver |journal=Am. J. Clin. Pathol. |volume=125 |issue=4 |pages=519–25 |year=2006 |month=April |pmid=16627262 |doi=10.1309/59TN-EFAL-UL5W-J94M |url=}}</ref> | HCC vs. ICC:<ref name=pmid16627262>{{cite journal |author=Lei JY, Bourne PA, diSant'Agnese PA, Huang J |title=Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver |journal=Am. J. Clin. Pathol. |volume=125 |issue=4 |pages=519–25 |year=2006 |month=April |pmid=16627262 |doi=10.1309/59TN-EFAL-UL5W-J94M |url=}}</ref> | ||
*TTF-1: ~90-100% +ve (cytoplasmic) in HCC vs. ~10% in cholangiocarcinoma. | *TTF-1: ~90-100% +ve (cytoplasmic) in HCC vs. ~10% in cholangiocarcinoma. | ||
==Molecular== | ==Molecular== | ||